Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dermira, Inc. (NASDAQ: DERM).

Full DD Report for DERM

You must become a subscriber to view this report.


Recent News from (NASDAQ: DERM)

Dermira provides launch update for QBREXZA cloth for primary axillary hyperhidrosis
Dermira, Inc. (NASDAQ: DERM ) announces several updates related to the upcoming launch and availability of QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. QBRE...
Source: SeekingAlpha
Date: September, 05 2018 08:41
Dermira Provides Launch Readiness Update for QBREXZA(TM) (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis
Early commercial payer coverage for the therapy includes Express Scripts, Inc. and OptumRx Company announces DermiraConnect, a new patient access program that will provide patients broad access to QBREXZA Therapy is expected to be available in pharmacies nationwide beginning October...
Source: GlobeNewswire
Date: September, 05 2018 07:30
Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, Inc. (NASDAQ:MNOV), Dermira, Inc. (NASDAQ:DERM), FRP Holdings...
Source: GlobeNewswire
Date: August, 20 2018 07:50
Dermira misses by $0.06, misses on revenue
Dermira (NASDAQ: DERM ): Q2 EPS of -$0.57 misses by $0.06 . Revenue of $39.1M (+3554.2% Y/Y) misses by $0.1M . Press Release More news on: Dermira, Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: August, 06 2018 16:53
Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update
- QBREXZA™ (glycopyrronium) cloth for the treatment of primary axillary hyperhidrosis approved in June 2018 - QBREXZA expected to be available nationwide in pharmacies beginning in October 2018 - Lebrikizumab Phase 2b enrollment expected to be completed by end of 2018 MENLO...
Source: GlobeNewswire
Date: August, 06 2018 16:01
Insider Weekends - Chairman Of Trucking Company Buys Shares Under A 10b5-1 Purchase Plan
Insider buying decreased significantly last week with insiders purchasing $20.33 million of stock compared to $220.22 million in the week prior. Selling, on the other hand, increased with insiders selling $937.49 million of stock last week compared to $823.77 million in the week prior. The per...
Source: SeekingAlpha
Date: July, 16 2018 07:49
Weekly Insider Trading, July 10
Weekly introduction Back to regular programming. This week, I cover transactions registered in the past two weeks. I also plan more formal updates of performance going forward. It will be a rough estimation though since I do not currently have a format on how to communicate exact entries a...
Source: SeekingAlpha
Date: July, 11 2018 19:55
Dermira May Provide Some Upside Potential, Even After Latest FDA Approval
Recently, Dermira ( DERM ) announced that it had received FDA approval for its drug Qbrexza to treat patients with Primary axillary hyperhidrosis. This latest FDA approval is the start of a turnaround for the company, but there is something else in the pipeline that could turn things aro...
Source: SeekingAlpha
Date: July, 02 2018 05:29
Evercore sees big market for new Dermira drug; shares +5.5%
Dermira (NASDAQ: DERM ) is up 5.5% , with Evercore seeing solid market opportunity after the company's prescription wipe for excessive underarm sweat won FDA approval . More news on: Dermira, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: June, 29 2018 11:02
Premarket Gainers as of 9:05 am (6/29/2018)
GEMP +114%  as Gemcabene drug candidate  met its primary endpoint . More news on: Gemphire Therapeutics, Echelon Corporation, Dermira, News on the U.S. economy, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: June, 29 2018 09:15

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.129.8410.199.52957,292
2018-05-1710.7110.8911.1710.63517,493
2017-02-0229.1128.9129.5028.885120,432
2017-02-0129.4729.3330.1428.95198,460
2017-01-3127.7629.4430.2827.32232,382

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1126,01558,78244.2567Short
2018-12-1055,67887,41263.6961Short
2018-12-0745,878111,24041.2424Short
2018-12-0658,532187,31331.2482Cover
2018-12-0486,157106,32881.0295Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DERM.


About Dermira, Inc. (NASDAQ: DERM)

Logo for Dermira, Inc. (NASDAQ: DERM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DERM)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 24 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: April, 10 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: March, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 05 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 22 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 22 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: DERM)

      Daily Technical Chart for (NASDAQ: DERM)


      Stay tuned for daily updates and more on (NASDAQ: DERM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DERM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DERM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of DERM and does not buy, sell, or trade any shares of DERM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/